Life Technologies releases range of ‘molecule-to-market’ bioproduction solutions

By Alexandria Pesic

- Last updated on GMT

Related tags: Cell line development, Cell culture

Californian biotech tool manufacturer Life Technologies has teamed with German contract research organisation (CRO) ProBiogen to release a range of royalty-free Gibco Freedom Cell Line Development Kits.

The new Freedom CHO-S and DG-44 kits include fully documented current good manufacturing practice (cGMP) cell lines, reagents, culture media and protocols, and are designed to simplify the early stages of new biological drug development.

“Life Technologies’’ cell line development kits showcase our ability to integrate proprietary technologies into simple, innovative solutions that accelerate the pathway from molecule to market,” ​said Mark Stevenson, president and chief operating officer of Life Technologies.

“Our royalty-free Freedom kits enable faster early stage development, and allow customers to focus on what they do best: developing new biologics to treat diseases.”

The company says its kits can reduce the time from transfection to stable cell line production from six to four months, thereby eliminating the need for time-consuming and complicated media adaptation steps.


Developed in collaboration with Berlin-based ProBiogen, Life says its Freedom CHO-S kit provides biopharma drug developers with all the key components needed to rapidly and systematically generate Chinese hamster ovary (CHO) cell lines.

The cells have been engineered to express recombinant proteins as therapeutics for the treatment of a range of diseases, including rheumatoid arthritis, anaemia, multiple sclerosis, cancer, and non-Hodgkin’s lymphoma.

According to Life, CHO cells play a critical part in the $20bn (€14bn) bioproduction market through their use in the development of clinical and commercial biologics.

Mixed results

The release of Life’s new cell line development kits comes soon after the company posted mixed financial results for Q1 2011.

Figures showed revenues for the period increased by barely 1 per cent year on year from $884.9m (€621m) in 2010 to $895.9m (€628.9m) - just short of the $905.4m (€635.6m) forecast by industry analysts.

Life put the cause down to the “extraordinary events that occurred in Japan”, ​which resulted delays to the launch of its 5500 SOLiD and 550 XL gene sequencers, and disrupted its manufacturing operations.

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us


View more